Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07733349) titled 'Phase I/II Clinical Trial of UX-DA003 Injection for the Treatment of Patients With Parkinson's Disease' on July 23.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Shanghai UniXell Biotechnology Co., Ltd
Condition:
Parkinson's Disease
Intervention:
Drug: UX-DA003
Recruitment Status: Not recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: August 3, 2026
Target Sample Size: 12
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/study/NCT0773334...